Vaccine, meningococcal


Concise Prescribing Info
Indications/Uses
Prophylaxis of meningococcal disease caused by N. meningitidis.
Dosage/Direction for Use
Adult : IM As serogroup B vaccine: Bexsero 2 doses of 0.5 mL given at least 1 mth apart. Trumenba 2 doses of 0.5 mL given at a 6 mth interval; or 3 doses of 0.5 mL w/ the 1st 2 doses at least 1 mth apart followed by a 3rd dose at least 4 mth after the 2nd dose. As conjugated serogroup C or ACWY vaccine: Single dose of 0.5 mL. SC As unconjugated serogroup ACWY vaccine: Single dose of 0.5 mL.
Dosage Details
Intramuscular
Meningococcal disease, prophylaxis
Adult: As N. meningitidis serogroup B vaccine (recombinant, adsorbed): Bexsero 2 doses of 0.5 mL given at least 1 mth apart. Trumenba 2 doses of 0.5 mL given at 6 mth interval; or 3 doses of 0.5 mL w/ the 1st 2 doses at least 1 mth apart followed by a 3rd dose at least 4 mth after the 2nd dose. As N. meningitidis serogroup C or ACWY conjugate vaccine (conjugated to diphtheria CRM197 or tetanus toxoid carrier protein): Single dose of 0.5 mL.
Child: As N. meningitidis serogroup B vaccine (recombinant, adsorbed): Bexsero 2-5 mth 3 doses of 0.5 mL at least 1 mth apart. Booster dose of 0.5 mL is given between 12-15 mth or not later than 24 mth of age; 6-11 mth (unvaccinated) 2 doses of 0.5 mL given at least 2 mth apart. Booster dose of 0.5 mL is given at 2 yr of age, w/ at least 2 mth interval from the primary series; 12-23 mth (unvaccinated) 2 doses of 0.5 mL given at least 2 mth apart. Booster dose of 0.5 mL is given 12-23 mth apart from the primary series; 2-10 yr 2 doses of 0.5 mL given at least 2 mth apart; ≥11 yr Same as adult dose. Trumenba ≥10 yr Same as adult dose. As N. meningitidis serogroup C vaccine (conjugated to diphtheria CRM197 protein): 2-12 mth 2 doses of 0.5 mL given at least 2 mth apart. Booster dose may be given based on national recommendations; >12 mth Same as adult dose. As N. meningitidis serogroup C vaccine (conjugated to tetanus toxoid carrier protein): 2-4 mth 2 doses of 0.5 mL given at least 2 mth apart. Booster dose of 0.5 mL is given at 12-13 mth of age w/ an interval of 6 mth after the last vaccination; >4 mth Same as adult dose. As N. meningitidis serogroup ACWY vaccine (conjugated to diphtheria CRM197 protein): ≥2 yr Same as adult dose. Booster dose of 0.5 mL may be given based on national recommendations. As N. meningitidis serogroup ACWY vaccine (conjugated to tetanus toxoid carrier protein): 6 wk to 12 mth 2 doses of 0.5 mL given at least 2 mth apart. Booster dose of 0.5 mL is given at 12 mth of age; >12 mth Same as adult dose. Booster dose of 0.5 mL may be given based on national recommendations.

Subcutaneous
Meningococcal disease, prophylaxis
Adult: As unconjugated N. meningitidis serogroup ACWY vaccine: Single dose of 0.5 mL.
Child: As unconjugated N. meningitidis serogroup ACWY vaccine: ≥2 yr Same as adult dose.
Contraindications
Hypersensitivity. Acute severe febrile illness.
Special Precautions
Patient w/ asplenia, acute malaria, thrombocytopenia, coagulation disorder, history of resp immaturity. Immunocompromised patients. Minor febrile and mild upper resp infection is not a reason to postpone immunisation. Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Anxiety-related reactions, hyperventilation or stress-related reactions, vasovagal reactions (e.g. syncope), post-vaccination febrile reactions, apnoea (premature infants), haematoma. Rarely, symptoms of meningism (e.g. neck pain/stiffness, photophobia).
Nervous: Drowsiness, impaired sleeping, unusual crying, headache, dizziness, seizures (including febrile seizures), irritability, malaise, fatigue, transient neurological reactions.
GI: Eating disorder (e.g. anorexia), diarrhoea, nausea, vomiting.
Resp: Wheezing.
Musculoskeletal: Arthralgia, myalgia.
Dermatologic: Pallor, rash, eczema, severe local reactions.
Immunologic: Angioedema.
Others: Fever, inj site reactions (e.g. swelling, erythema, tenderness/pain).
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis).
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Resp monitoring for 48-72 hr in premature infants and patient w/ history of resp immaturity.
Drug Interactions
Immunosuppressive drugs may reduce the immune response to meningococcal vaccine.
Action
Description: Meningococcal vaccine contains purified polysaccharide antigens from Neisseria meningitidis (N. meningitidis). It is available either as monovalent which contains one serotype antigen or polyvalent, containing 2 or more serotypes antigen. It can also be conjugated to a carrier protein (e.g. diphtheria CRM197, tetanus toxoid) to increase immunogenicity. It stimulates the production of bactericidal antibodies against N. meningitidis serogroups A, C, W-135, Y (ACWY), and B. It is usually given via IM route w/ SC route reserved for patients w/ bleeding disorder.
Storage
Store between 2-8°C. Do not freeze. Protect from light.
ATC Classification
J07AH - Meningococcal vaccines ; Used for active immunizations.
References
Anon. Meningococcal Group B Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/08/2017.

Anon. Meningococcal Groups A, C, Y, and W-135 Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/08/2017.

Anon. Meningococcal Polysaccharide Vaccine (Groups A/C/Y and W-135). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/08/2017.

Buckingham R (ed). Meningococcal Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/08/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Meningococcal Group B Vaccine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/08/2017.

Sanofi-Aventis New Zealand Limited. Menomune ACYW-135 Vaccine data sheet 7 June 2013. Medsafe. http://www.medsafe.govt.nz/. Accessed 08/08/2017.

Disclaimer: This information is independently developed by MIMS based on Vaccine, meningococcal from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Mencevax ACWY
  • Menomune-A/C/Y/W-135
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in